„The Report Human Immunodeficiency Virus (HIV) Infections (AIDS) Global Clinical Trials Review, H2, 2016 provides information on pricing, market analysis,
GlobalData’s clinical trial report, Human Immunodeficiency Virus (HIV) Infections (AIDS) Global Clinical Trials Review, H2, 2016 „provides an overview of Human Immunodeficiency Virus (HIV) infections (AIDS) clinical trials scenario The clinical trials of human immunodeficiency virus (HIV) infections (AIDS). (G7 & E7 ), The clinical trials, the clinical trials, the clinical trials, the clinical trials, the clinical trials, the clinical trials, the clinical trials and the clinical trials. Clinical trials database are periodically updated by dynamic process.
The report enhances the decision making capabilities and helps to create an effective counter.
View Report At http://www.marketresearchreports.biz/analysis/879214
Scope
– The report provides a snapshot of the global clinical trials landscape
– Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
(Trial title, Phase, and Status) pertaining to the company
– The report provides all the unaccomplished trials (Terminated, Suspended, and Withdrawn) with reason for unaccomplishment
– The Report provides enrollment trends for the past five years
– Report provides the latest news for the past three months
Reasons to buy
– Assists in formulating key business strategies with regards to investment
– Helps in identifying prominent locations for clinical trials which saves time and cost
– Provides top level analysis of Global Clinical Trials Market
<br> <br> <br> <br> <br> <br> <br> <br> <br> <br> <br> <br> <br> <br> <br> <br> <br> <br> <br> <br> <br> <br> <br> <br> <br> <br> Supporting trials and globalization markets
(Terminated, suspended or withdrawn) trials
– Facilitates clinical trial assessment of the indication on a global, regional and country level
Download Sample copy of this report at:
http://www.marketresearchreports.biz/sample/sample/879214
Table of Contents
Table of Contents
Table of Contents
List of Tables 3
List of Figures 4
Report Guidance 5
Clinical Trials by Region 6
Clinical Trials and Average Enrollment by Country 7
Top Five Countries Contributing to Clinical Trials in Asia-Pacific 10
Top Five Countries Contributing to Clinical Trials in Europe 11
Top Countries Contributing to Clinical Trials in North America 12
Top Five Countries Contributing to Clinical Trials in Middle East and Africa 13
Top Five Countries Contributing to Clinical Trials in Central and South America 14
Clinical Trials by G7 Countries: Proportion of Human Immunodeficiency Virus (HIV) Infections (AIDS) to Infectious Disease Clinical Trials 15
Clinical Trials by Phase in G7 Countries 17
Clinical trials in G7 Countries by Trial Status 18
Clinical Trials by E7 Countries: Proportion of Human Immunodeficiency Virus (HIV) Infections (AIDS) to Infectious Disease Clinical Trials 19
Clinical Trials by Phase in E7 Countries 21
Clinical Trials in E7 Countries by Trial Status 22
Clinical Trials by Phase 23
In Progress Trials by Phase 24
Clinical Trials by Trial Status 25
Clinical Trials by Endpoint Status 26
Subjects Recruited Over a Period of Time
Clinical Trials by Sponsor Type 28
Prominent Sponsors 29
Top Companies Participating in Human Immunodeficiency Virus (HIV) Infections (AIDS) Therapeutics Clinical Trials 30
Prominent Drugs 32
Latest Clinical Trials News on Human Immunodeficiency Virus (HIV) Infections (AIDS) 33
Oct 06, 2016: CytoDyn Announces Favorable Protocol Modifications for Pivotal Phase 3 Combination Trial With PRO 140 AfterPositive FDA Meeting 33
Sep 13, 2016: ABIVAX Completes the Second Milestone in CaReNa, a Strategic Industrial Innovation Project Supported by Bpifrance 33
Aug 23, 2016: Patients Approach Two Years of Complete HIV Viral Load Suppression in Phase 2b PRO 140 Monotherapy Extension Study 34
Aug 18, 2016: Ibalizumab Phase III Study Primary End-Point Results to Be Presented at IDWeek 2016 35
Aug 16, 2016: ViiV Healthcare launches phase III program evaluating a two-drug regimen combining dolutegravir and lamivudine for HIV-1 treatment 35
Jul 26, 2016: SMILE Trial Launch – investigating a potentially lower toxicity, simplified treatment regimen for HIV infected children 35
Clinical Trial Profile Snapshots 36
Appendix 2794
Abbreviations 2794
Definitions 2794
Research Methodology 2795
Secondary Research 2795
About GlobalData 2796
Contact Us 2796
Disclaimer 2796
Source
Read our latest Press Release at
http://www.marketresearchreports.biz/pressreleases
About us
MarketResearchReports.biz is the most comprehensive collection of market research reports. MarketResearchReports.Biz services are specially designed to save time and money for our clients. We are a one-stop solution for all your research needs, our main offerings are syndicated research reports, custom research, subscription and consulting services. We serve all sizes and types of companies spanning across various industries.
Contact
State Tower
90 Sate Street, Suite 700
Albany, NY 12207
Tel: + 1-518-621-2074